• Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

(970) 818-8343

info@cetya-therapeutics.com
Cetya Therapeutics Cetya Therapeutics
  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

About sambasci

This author hasn't written their bio yet.
sambasci has contributed 4 entries to our website, so far.

1Cetya Therapeutics Appoints Ron Lowy to Board of Directors

Cetya Therapeutics Appoints Ron Lowy to Board of Directors

Jul 1, 2020

Adds extensive life science senior experience and transactional capability to the Board of Directors Fort Collins, CO, July 1, 2020 – Cetya Therapeutics, Inc. announces the appointment of Mr. Ron A. Lowy to its Board of Directors. Mr. Lowy fills a vacant position due to the passing of Founding Scientist Robert Williams, PhD, in May. […]

2Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102

Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102

Jun 11, 2020

Drug candidate active against EGFR and KRAS mutant lung cancer cell lines Fort Collins, CO, June xx, 2020 – Cetya Therapeutics, Inc. today announced issuance of US Patent No. 10,676,504 and Australian Patent No. 2016229324 covering CT-102, Cetya’s proprietary HDAC inhibitor. CT-102 has demonstrated excellent activity in vitro against difficult to treat lung cell lines. […]

3Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors

Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors

Jan 29, 2020

Novel Chemistry Allows Conjugation of Largazole Analogs to Receptor Ligands or Other Cytotoxic Agents Fort Collins, CO, January 21, 2020 – Cetya Therapeutics, Inc. today announced issuance of US Patent No. 10,538,534 covering Cetya’s novel ability to conjugate receptor ligands or other cytotoxic agents to its unique HDAC inhibitors, creating targeted and dual-acting anticancer compounds. […]

4Cetya Therapeutics Announces Phase II STTR Grant Award

Cetya Therapeutics Announces Phase II STTR Grant Award

Sep 23, 2019

 $1,000,000 NIH Grant will further development of Cetya’s HDAC inhibitor CT-101 for treatment of sickle cell disease   Fort Collins, CO, September 17, 2019 – Cetya Therapeutics, Inc. announces the award of a $1,000,000 Phase II STTR grant from the National Heart, Lung and Blood Institute of NIH to support the in vivo assessment of its […]

Recent Posts

  • Cetya Therapeutics welcomes Dr. Anthony Wutoh to its Board of Directors
  • Cetya Therapeutics Appoints Ron Lowy to Board of Directors
  • Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102
  • Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors
  • Cetya Therapeutics Announces Phase II STTR Grant Award

Contact Us

We're currently offline. Send us an email and we'll get back to you, asap.

Send Message

Menu

  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

Contact

  • (303) 895-8216
  • info@cetya-therapeutics.com
Cetya Therapeutics, Inc.

2401 Research Boulevard, Suite 204
Fort Collins, CO 80526

© 2018 · Cetya Therapeutics